The United Kingdom and the United States have secured a major bilateral deal that will guarantee no duties on UK drug shipments going into the American market.
Key Provisions of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase spending on pharmaceuticals through the NHS. This move secures that duties on these crucial products will remain at nothing for a period of three years.
This agreement is in response to earlier threats to dramatically increase tariffs on branded pharmaceutical imports, with increases mentioned as high as double the cost.
"This agreement between the UK reinforces the global environment for innovative medicines and establishes much-needed fairness to transatlantic pharmaceutical trade," a release said.
Trade Importance
Medicines represent one of the the United Kingdom's biggest exports to the US, which is easily the biggest buyer for large companies like GSK and AstraZeneca.
Trade data indicate that in the year to the end of September, the UK exported drugs valued at over eleven billion pounds to the US. This value represented 17.4% of total UK exports in that period.
"This guarantee secures work, boosts funding and sets the stage for the UK to establish itself as a worldwide center for life sciences," a government official remarked.
Specific UK Commitments
The deal entails several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it judges new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to increase total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount manufacturers must return to the NHS to stay within budget will be limited at fifteen percent. Last year, refunds exceeded 20%.
Broader Context
The deal comes amid a protracted dispute between the drug companies and the UK government over spending levels and approval rates.
This friction were heightened by claims that US customers were charged a premium for the same drugs than people in the UK and Europe.
In recent months, several large manufacturing plans in the UK have been halted or scrapped, while major investments have been directed toward American operations.
One official stated that the NHS had to spend more on medicines, noting that its budget allocation on drugs had declined as a proportion of its overall budget over the previous ten-year period.
